Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Macfarlane Burnet Institute For Medical Research And Public Health Limited has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This prosecution is handled by 1 distinct examiner and 1 distinct art unit. CHESTNUT, BARRY A is the busiest examiner, with 1 pending office action. The portfolio's current activity is highly focused, with all pending feedback coming from a single examiner within the Biotechnology & Pharmaceuticals sector.
Practitioners should focus exclusively on the preferences of CHESTNUT, BARRY A to advance this case. The lack of multiple pending actions or examiners means there is no internal baseline for comparing prosecution success or examiner behavior. This company's strategy is currently tied to the resolution of this 1 pending office action. The outcome of this single case will define the current success of the patenting effort, making the interaction with the 1 distinct examiner the central element of the prosecution process. This singular focus within 1 art unit simplifies the administrative tracking but increases the impact of any single examiner's decision on the overall portfolio. The company must ensure that its responses are perfectly tailored to the expectations of this specific examiner to avoid further delays.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHESTNUT, BARRY A | 1 | 73.9% | +6.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18682740 | Vaccine Antigen | CHESTNUT, BARRY A | — |
| Art Unit | Apps |
|---|---|
| 1672 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18682740 | Vaccine Antigen | CHESTNUT, BARRY A | 1672 | §102§112 | Non-Final OA | — | Pending | Feb 09, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialMacfarlane Burnet Institute For Medical Research And Public Health Limited has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Barry A Chestnut has the most, with 1 of Macfarlane Burnet Institute For Medical Research And Public Health Limited's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
